Ubicom Holdings. Inc. · TSE:3937
Ubicom — FY2026 Q1 Earnings Presentation
39 slides from Ubicom's earnings presentation, Aug 13, 2026
Slide 1: FY2026 Q1 Financial Results Materials
Ubicom Holdings, Inc. (Standard Market of TSE: 3937) FY2026 Q1 Financial Results Materials * In these materials, the "AI Technology Strategy Business" is presented under its new name following the organizational restructuring effective July 1, 2026. In the "Consolidated Financial Results for the Thr
Slide 2: Table of Contents
Table of Contents 01 Highlights of Consolidated Financial Results for FY2026 Q1 P.3 02 Overview of Consolidated Financial Results (P/L) for FY2026 Q1 P.4 03 Medical Business P.5 04 AI Technology Strategy Business P.14 05 Dividend Policy P.22 06 Business Forecast ＆ Performance Trends P.24 07 Appendix
Slide 3: Highlights of Consolidated Financial Results for FY2026 Q1
Highlights of Consolidated Financial Results for FY2026 Q1 Company performance: In FY2026 Q1, sales, operating income and ordinary income all exceeded the same period of the previous year, marking record highs for a first quarter. Operating income grew 30.9% and ordinary income grew 25.0% year on
Slide 4: Overview of Consolidated Financial Results (P/L) for FY2026 Q1
Overview of Consolidated Financial Results (P/L) for FY2026 Q1 Sales, operating income and ordinary income all reached record highs for a first quarter. Operating income grew 30.9% and ordinary income grew 25.0% year on year, expanding steadily. Meanwhile, net income declined year on year due to tem
Slide 5: Medical Business
Medical Business 5
Slide 6: Medical Business: Overview by Segment for FY2026 Q1
Medical Business: Overview by Segment for FY2026 Q1 (Business Performance) As a medical platform provider, we achieved record-high revenue and operating profit, driven by steady growth in recurring revenue from the Mighty series and expanded business scale through M&A. Despite goodwill amortization
Slide 7: AI×Subscription Model: Mighty Series User Base Trend
AI×Subscription Model: Mighty Series User Base Trend Healthcare DX investment accelerated following physician work-style reforms and medical fee revisions in April 2024, driving steady growth in new users alongside existing customer migration. Hospitals （Unit: properties） 22,912 23,157 Clinics 21,94
Slide 8: Medical Business Performance Trends
Medical Business Performance Trends M&A initiatives have steadily strengthened the earnings foundation, resulting in continuous growth in both revenue and operating profit. Following the consolidation of Radianceware (operating margin approx. 17%) from April 1, 2026, profit margins temporarily decli
Slide 9: Driving Profitability Improvement through Cross-Selling and Direct Sales Expansion
Driving Profitability Improvement through Cross-Selling and Direct Sales Expansion Radianceware’s contribution from FY2026 Q1 and enhanced collaboration across the three Group companies (customers, products, and sales capabilities) will drive further growth. Leveraging a strengthened earnings base,
Slide 10: Strategy to maximize Radianceware's profitability
Strategy to maximize Radianceware’s profitability Leveraging Medical Business consulting resources to strengthen Radianceware’s EMR implementation support capabilities, address talent shortages, and expand order opportunities. Cross-selling the “Mighty” series supports healthcare institutions im
Slide 11: The "Mighty" Series: AI-Driven, High-Margin Recurring Revenue Core Solutions
The “Mighty” Series: AI-Driven, High-Margin Recurring Revenue Core Solutions By implementing the “Mighty” series, healthcare institutions improve profitability and reduce costs. These operational benefits can also strengthen proposals for EMR and related systems. Key Challenges in the 医療機関が抱える課題 Hea
Slide 12: Long-Term Strategy: M&A Strategy (Nationwide Distributor Acquisitions)
Long-Term Strategy: M&A Strategy (Nationwide Distributor Acquisitions) From 2025 through 2030, the Company will advance a Group direct sales model through strategic M&A initiatives aimed at maximizing the profitability of the Medical Business. Phase 2: Subsidiary Acquisition 2030 VISION Approved the
Slide 13: Scenarios for Medium to Long-Term Growth in the Medical Business
Scenarios for Medium to Long-Term Growth in the Medical Business Driving mid- to long-term growth through two engines: organic growth of stable recurring revenue and inorganic growth through M&A. M&A serves as a strategic investment to expand customer reach, strengthen sales channels, and enhance fu
Slide 14: AI Technology Strategy Business
AI Technology Strategy Business 14
Slide 15: AI Technology Strategy Business: Overview by Segment for FY2026 Q1
AI Technology Strategy Business: Overview by Segment for FY2026 Q1 (Business Performance) The establishment of the AI-driven development framework was completed, and both sales and operating income reached record highs, driven by revenue growth and cost structure reforms at the Philippine subsidiary
Slide 16: Philippine Subsidiary: Evolving to a Global AI Profit Center
Philippine Subsidiary: Evolving from a "Development Base" to a "Global AI Profit Center" The Philippine subsidiary achieved record highs in both sales and operating income. Under the Go Global strategy, the expansion of direct-contract projects, including with leading companies in the U.S. healt
Slide 17: Business Model Transformation to an AI-Driven Development Framework
Overview of the Business Model Transformation to an AI-Driven Development Framework AI Technology Strategy Business－Growth Strategy Overview, FY2026 Onward Aiming to move away from the man-month model dependent on “headcount × time,” the Company is advancing its transition to an “AI-driven develop
Slide 18: Business Model Transformation through AI-Driven Development
Business Model Transformation through AI-Driven Development Starting from AI-driven development, the Company is shifting from a "man-month dependent" model to a "small-team, high value-added" development model. Initiative Content Phase Progress 【FY2025 Q3 – Q4】 • Analyzed watsonx assets using the Co
Slide 19: Launch of "ALSEA" Utilization in the IBM Japan Project
Launch of "ALSEA" Utilization in the IBM Japan Project In the IBM Japan project, the Company has begun utilizing "ALSEA" in addition to "IBM Bob," strengthening its capability to handle high value-added enterprise projects and aiming to improve profitability. ① Technology foundation Technology Role
Slide 20: Overview of AI Use Cases (by Industry)
Overview of AI Use Cases (by Industry) AI is utilized across areas including the upstream phase (requirements definition), and cross-industry AI adoption is expanding. With the establishment of the AI-driven development framework complete, the Company is accelerating the creation of high value-added
Slide 21: Target Domains for Building an AI-Driven Development Framework
Target Domains for Building an AI-Driven Development Framework The generative AI market is expected to expand over the medium to long term both in Japan and worldwide, with growing demand for AI utilization across industrial domains such as finance, manufacturing, healthcare, and energy. The governm
Slide 22: Dividend Policy
Dividend Policy 22
Slide 23: A dividend policy enabling shareholders to directly benefit from growth
A dividend policy enabling shareholders to directly benefit from growth 【Dividend Policies】 ① Although FY2025 results fell short of the initial forecast due to temporary impacts from growth investments and business portfolio optimization, the Medical Business continued to strengthen its earnings fou
Slide 24: Business Forecast & Performance Trends
Business Forecast & Performance Trends 24
Slide 25: Earnings Forecast and Financial Performance Trend
Earnings Forecast and Financial Performance Trend [Earnings Forecast] • For FY2026 forecast, we expect further expansion of the revenue base in the medical business and contributions from newly acquired subsidiaries through M&A. • The forecast incorporates higher depreciation expenses related to the
Slide 26: Earnings Forecast and Financial Performance Trend: Key Strategic Initiatives
Earnings Forecast and Financial Performance Trend 【Key Strategic Initiatives】 ① Continuous execution of M&A strategy The company will continuously promote M&A to expand its revenue base and accelerate the accumulation of recurring income. Early realization of synergies will be achieved through post-
Slide 27: Appendix
Appendix 27
Slide 28: Our Business Model: A Model for Resolving Social Issues in Japan
Our Business Model: A Model for Resolving Social Issues in Japan, A Developed Country Facing Challenges 01 Medical Business 02 AI Technology Strategy Business Reforming the workstyle of Against the backdrop of an medical professionals anticipated shortage of 3.26 million Improving the profitability
Slide 29: Medical Business: The Tailwind Created by Social Issues and Political Measures
Medical Business: The Tailwind Created by Social Issues and Political Measures (Market Environment) Increasing deficits of medical institutions and social security spending cuts: three growth opportunities arising from structural challenges Increasing deficits in The coverage rate of EMR is Business
Slide 30: Medical Business: Impact of M&A Strategy Execution (KPI Changes)
Medical Business: Impact of M&A Strategy Execution (KPI Changes) Over the five years from 2025 to 2030, we will execute 8 to 10 M&A deals with the aim of increasing the Company's direct sales ratio. ＜Factors contributing to LTV *1 improvement＞ Content Measurement details Increase of ①Inclusion of ag
Slide 31: Medical Business: Revenue Recognition Methods (Billing Methods)
Medical Business：Revenue Recognition Methods (Billing Methods) License revenue for the Mighty series adopts a “instalment recognition” method. With the increase in contract numbers, sales steadily accumulate on a monthly basis, achieving revenue stabilization. Furthermore, the AI × subscription mode
Slide 32: M&A Strategy Phase 2: Maximizing Medical Business Profitability
M&A Strategy Phase 2: Maximizing Medical Business Profitability Radianceware Financial Performance Trend Over the Quantitative Evaluation and Investment Past Three Years Decision for This M&A （Unitmillion yen) Sales 3 consecutive years of ① Comparison with Target Payback Period revenue and profit Th
Slide 33: Launch of New Product "MightyChecker Cloud X" (April 2026)
Launch of New Product “MightyChecker® Cloud X” N e x t - g e n e r a t i o n c l o u d - b a s e d me d i ca l c l a i ms i n s p e c t i o n s o f t w a re Launch of New Product “MightyChecker® Cloud X” (April 2026) Features of MightyChecker® Cloud X Targets Improved Operational Efficiency Migratio
Slide 34: "Insurance Knowledge Platform" Driving DX in the Insurance Industry
“Insurance Knowledge Platform” Driving DX in the Insurance Industry Leveraging a proprietary medical data infrastructure accumulated over 40 years and AI-based diagnostic prediction capabilities, the Company is promoting digital transformation (DX) for insurance companies. It provides a business sup
Slide 35: Promotion of Group Businesses Based on Social Significance
Promotion of Group Businesses Based on Social Significance Provision of solutions that are beneficial to three key areas: pressing need for workstyle Growing demand due to the reforms for medical doctors, improvement in reassessment of offshore development management of medical institutions, and DX
Slide 36: ESG: For sustainable growth of business, society, and client companies
ESG：For sustainable growth of business, society, and client companies Goals Concrete Activities Related SDGs ・To make the electric power consumed E ・To reduce CO2 emissions at the head office 100% derived from renewable energy ・Global partnership ・Investment in equipment of subsidiaries in the Phili
Slide 37: Corporate Profile
Corporate Profile ■Corporate name: Ubicom Holdings, Inc. (Standard Market of TSE: 3937) ■Strategic markets: healthcare, finance, public services, automobiles, manufacturing, robotics, real estate, energy, etc. ■Business description: AI Technology Strategy Business In order to solve the problem of sh
Slide 38: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements The materials and information provided in this announcement include forward-looking statements based on our current estimates and expectations at this point of time. Such forward-looking statements are subject to various risks and uncertaintie
Slide 39: Holdings, Inc.
Holdings, Inc. = fe) Q Q =) 39